114 related articles for article (PubMed ID: 8320837)
21. Effect of an angiotensin receptor antagonist, TCV-116, on sympathetic nerve activity in patients with essential hypertension.
Ashino K; Gotoh E; Sumita S; Takasaki I; Sugimoto K; Shionoiri H; Ishii M
Blood Press Suppl; 1994; 5():122-9. PubMed ID: 7889194
[TBL] [Abstract][Full Text] [Related]
22. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
Kubo K; Kohara Y; Imamiya E; Sugiura Y; Inada Y; Furukawa Y; Nishikawa K; Naka T
J Med Chem; 1993 Jul; 36(15):2182-95. PubMed ID: 8340921
[TBL] [Abstract][Full Text] [Related]
23. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery.
Tazawa S; Nakane T; Chiba S
J Pharmacol Exp Ther; 1999 Feb; 288(2):898-904. PubMed ID: 9918604
[TBL] [Abstract][Full Text] [Related]
25. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Kim S; Iwao H
J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
[TBL] [Abstract][Full Text] [Related]
26. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis.
Fujita M; Hayashi I; Yamashina S; Itoman M; Majima M
Biochem Biophys Res Commun; 2002 Jun; 294(2):441-7. PubMed ID: 12051731
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Burnier M; Buclin T; Biollaz J; Nussberger J; Waeber B; Brunner HR
Kidney Int Suppl; 1996 Jun; 55():S24-9. PubMed ID: 8743506
[No Abstract] [Full Text] [Related]
28. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.
Brilla CG; Scheer C; Rupp H
J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122
[TBL] [Abstract][Full Text] [Related]
29. AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats.
Sugimoto K; Gotoh E; Takasaki I; Ebina T; Iwamoto T; Takizawa T; Shionoiri H; Ishii M
Clin Exp Pharmacol Physiol; 1996 Apr; 23(4):282-6. PubMed ID: 8717062
[TBL] [Abstract][Full Text] [Related]
30. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.
Chiu AT; McCall DE; Price WA; Wong PC; Carini DJ; Duncia JV; Wexler RR; Yoo SE; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):711-8. PubMed ID: 2313596
[TBL] [Abstract][Full Text] [Related]
31. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
Unger T
Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.
Kim S; Ohta K; Hamaguchi A; Omura T; Yukimura T; Miura K; Inada Y; Ishimura Y; Chatani F; Iwao H
J Pharmacol Exp Ther; 1995 Apr; 273(1):509-15. PubMed ID: 7714806
[TBL] [Abstract][Full Text] [Related]
33. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
Ohlstein EH; Gellai M; Brooks DP; Vickery L; Jugus J; Sulpizio A; Ruffolo RR; Weinstock J; Edwards RM
J Pharmacol Exp Ther; 1992 Aug; 262(2):595-601. PubMed ID: 1501114
[TBL] [Abstract][Full Text] [Related]
34. [Nonpeptide angiotensin II antagonists].
Shionoiri H; Takasaki I; Sugimoto K; Minamisawa K
Nihon Rinsho; 1992 Apr; 50 Suppl():753-63. PubMed ID: 1635263
[No Abstract] [Full Text] [Related]
35. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers.
Belz GG; Fuchs B; Malerczyk C; Magin SG; Roll S; Mutschler E
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S45-7. PubMed ID: 9331006
[No Abstract] [Full Text] [Related]
36. The diversified pharmacology of angiotensin II-receptor blockade.
Timmermans PB; Smith RD
Blood Press Suppl; 1996; 2():53-61. PubMed ID: 8913541
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog.
Miyazaki M; Shiota N; Sakonjo H; Takai S
Jpn J Pharmacol; 1999 Apr; 79(4):455-60. PubMed ID: 10361885
[TBL] [Abstract][Full Text] [Related]
38. Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects.
Ogihara T; Nagano M; Higaki J; Kohara K; Mikami H
J Cardiovasc Pharmacol; 1995 Sep; 26(3):490-4. PubMed ID: 8583793
[TBL] [Abstract][Full Text] [Related]
39. Hypotensive effects of an angiotensin II type 1 receptor antagonist differ between exercised and sedentary rats aged from 4 to 19 weeks.
Fujii N; Nagashima S; Yukawa K; Miyauchi T; Maki S; Sakai S; Murakami K; Miyazaki H
Jpn J Physiol; 1998 Jun; 48(3):215-8. PubMed ID: 9689152
[TBL] [Abstract][Full Text] [Related]
40. Studies on nonpeptide angiotensin II receptor antagonists. IV. Synthesis and biological evaluation of 4-acrylamide-1H-imidazole derivatives.
Okazaki T; Watanabe T; Kikuchi K; Suga A; Shibasaki M; Fujimori A; Inagaki O; Yanagisawa I
Chem Pharm Bull (Tokyo); 1998 Jun; 46(6):973-81. PubMed ID: 9658576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
